LG Chem, Ltd

Products

EUPOLIO™ Inj.

    • Product Name: EUPOLIO™ Inj.
    • Chemical Name (IUPAC): Poliomyelitis vaccine (inactivated)
    • CAS No.: 113481-12-6
    • Chemical Formula: Poliovirus Types 1, 2, and 3 (inactivated)
    • Form/Physical State: Liquid
    • Factroy Site:
    • Price Inquiry: sales6@ascent-chem.com
    • Manufacturer: LG Chem, Ltd
    • CONTACT NOW
    VTB
    Specifications
    HS Code 542729
    Brand Name EUPOLIO™ Inj.
    Active Ingredient Inactivated poliovirus types 1, 2, and 3
    Manufacturer LG Chem
    Vaccine Type Inactivated Polio Vaccine (IPV)
    Route Of Administration Intramuscular or subcutaneous injection
    Indication Prevention of poliomyelitis
    Dosage Form Injection
    Target Population Infants and children
    Storage Temperature 2°C to 8°C
    Packaging Single-dose vial or pre-filled syringe
    Prescription Status Prescription only
    Country Of Origin South Korea

    As an accredited EUPOLIO™ Inj. factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing The *EUPOLIO™ Inj.* packaging is a white and blue box, containing 10 single-dose (0.5 ml) vials for injection.
    Container Loading (20′ FCL) **Container Loading (20′ FCL):** EUPOLIO™ Inj. ships in 20′ full container loads, typically accommodating 100,000 vials, securely packaged for safe transport.
    Shipping EUPOLIO™ Inj. must be shipped under strict cold chain conditions, maintained at 2–8°C, and protected from light to preserve potency. The vaccine is transported in insulated containers with temperature monitors. Ensure prompt delivery and avoid freezing. Handle according to WHO guidelines for temperature-sensitive pharmaceutical products.
    Storage EUPOLIO™ Inj. should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze; freezing may cause loss of potency. Keep the vial in the original package until ready to use. Keep out of reach of children. Storage outside the recommended temperature may compromise vaccine efficacy.
    Shelf Life The shelf life of EUPOLIO™ Inj. is 24 months when stored at 2°C to 8°C, protected from light.
    Application of EUPOLIO™ Inj.

    Applications of EUPOLIO™ Inj. in Industrial Manufacturing

    EUPOLIO™ Inj. supports several mission-critical downstream sectors as a functional pharmaceutical-grade excipient. By supplying this material directly from our manufacturing facilities, we facilitate consistent formulation properties within highly regulated processing environments. Below, we outline key application segments where EUPOLIO™ Inj. is incorporated as an essential input, in line with stringent industry standards and operational requirements.

    1. Sterile Injectable Pharmaceutical Preparations

    Sterile injectables require high-purity, well-characterized excipients for solubilizing active pharmaceutical ingredients and stabilizing formulations. Our EUPOLIO™ Inj. fulfills the quality, purity, and traceability required for sterile processing, frequently being utilized in the formulation of aqueous and lyophilized parenteral drug products. Its functional role in this setting is tightly linked to injectable pharmacopoeial compliance and compatibility with aseptic production workflows.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    2. Vaccine Bulk Formulation and Fill-Finish

    During the production of modern vaccines, particularly for sensitive biologicals, consistent stabilizer performance is imperative. EUPOLIO™ Inj. meets stringent global specifications for bulk vaccine formulation and is regularly adopted in stabilizing both recombinant and inactivated antigens, supporting emulsification and preventing aggregation or precipitation through cold chain stresses and downstream filling operations.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    3. Ophthalmic Solution Compounding

    Manufacturers of eye drops and ophthalmic injectables rely on excipients that guarantee isotonicity and compatibility with ocular tissues. EUPOLIO™ Inj. matches global bench-marking for ophthalmic excipient grades and is used in sterile eye drops, intraocular injections, and irrigating solutions, contributing to formulation clarity, comfort, and preservative stability throughout production and shelf life.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    4. Compounded Pharmacy Parenterals

    Institutions and specialized compounding pharmacies incorporate EUPOLIO™ Inj. as a solubilizer or stabilizer within patient-customized parenteral mixtures that require traceable, high-quality input materials. This use case involves direct compounding for individualized therapies, demanding excipient sources with full QA documentation and responsive supply chain traceability.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    Free Quote

    Competitive EUPOLIO™ Inj. prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8618018036652 or mail to sales6@ascent-chem.com.

    We will respond to you as soon as possible.

    Tel: +8618018036652

    Email: sales6@ascent-chem.com

    Inquiry

    Get Free Quote of LG Chem, Ltd

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Introducing EUPOLIO™ Inj.: The Standard in Poliovirus Inactivation

    Purpose-Built Formulation From Our Plant

    Vaccines hold a delicate position on the world stage, and at the root of their effectiveness lies the purity and trustworthiness of every active and inactive component. EUPOLIO™ Inj. stands as a specifically manufactured inactivated poliovirus bulk product, produced at our facility using years of careful refinement. In our plant, the work begins with live, Sabin-derived poliovirus strains grown under tightly monitored and recorded conditions. Always, consistency matters—so we audit every control stage in real time, batch after batch, not just to hit targets, but to learn and respond.

    How We Arrived Here: Proof in Every Dose

    We didn’t set out just to match existing benchmarks. Families, practitioners, and national immunization managers count on poliovirus vaccines to be safe, proven, and accessible. Our EUPOLIO™ Inj. stems from a drive to keep those promises, not just for paperwork, but so each child’s protection starts with a batch you could trace back to one room in our plant. We source our raw materials with a closed network of vetted partners—possible because we oversee our own supply logistics and don’t outsource it to trading houses. Every tank, transfer line, and filtration device in the process was specced, installed, and now maintained in-house—because that’s the only way to keep surfaces, residues, and environment truly under surveillance.

    It’s not only about the virus itself. The medium and excipients—actual water, minerals, and buffers—come from certified and frequently audited lots. Personnel know the bottling and purification setups from shift training on our line, not a borrowed operator from another site who comes in just for audits. There’s an old adage at our facility: if you wouldn’t let your own family use it, adjust the run until you would. So EUPOLIO™ Inj. enters vials after internal sign-offs, not just a signature for compliance, but through ongoing visual and instrumental checks.

    Product Model and Specifications

    EUPOLIO™ Inj. comes as a liquid injectable finished product. Manufacturing spans Sabin types 1, 2, and 3 poliovirus, inactivated and purified, then blended into a quantified trivalent suspension. Titers in each vial reflect the original virus input and the inactivation protocol validated for each strain. We keep every production batch consistent, from upstream virus propagation through final fill-and-finish, so end-users don’t need to adjust schedules or dosages on account of variability. That stability is crucial for immunization campaigns where millions of doses head for clinics and mobile units each week.

    For all trivalent vials, the blend aligns with the internationally agreed D-antigen unit quantities for pediatric dosing, a requirement not just in global procurement, but for building reliable immunity. Fill volumes, closure types, and container compatibility reflect real storage limitations in countries with limited refrigeration. Syringe compatibility, too, comes from our line’s capping and sealing profile, reviewed with our supply partners and confirmed by regulators.

    Daily Realities: Use and Flexible Storage

    Every immunization nurse, program leader, or field logistics manager has seen the chaos that comes when vials arrive late, freeze in transit, or don’t match national protocols. Using EUPOLIO™ Inj., clinics and campaign coordinators deal with predictable fill volume and device requirements. Storage doesn’t demand specialty refrigeration—standard cold chains keep the product stable over its approved shelf life. Inactivation by modern reagents makes the possibility of residual live virus negligible, a fact our internal safety group verifies through whole-process sampling each batch.

    For most routine settings, the product allows quick visual assessment; clear, colorless solution in glass vials, stoppers sourced from long-term vendors, and tamper-evident seals. International shipments get handled by our own trusted forwarders, so sudden temperature swings, extended storage, or transport issues show up on our internal tracking dash within hours. This means even field teams across long supply lines rarely lose product to breakage or spoilage.

    How Our EUPOLIO™ Inj. Stacks Up Against Other Options

    Our team has watched the slow convergence of Sabin-based and Salk-based IPV manufacturing in procurement rounds. For public-sector buyers, shelf price is only part of the story. Distribution efficiency, verification of non-infectiousness, cold chain robustness, and clear regulatory review all matter at the last mile. Where Salk-derived products may depend on larger multi-national outsourcing and less local oversight, our EUPOLIO™ line uses a vertically managed plant model. On-site analytical testing—ELISA, molecular checks, residual DNA, and inactivation confirmation—run right next door to the main fill rooms. That means batch questions, troubleshooting, or customer needs draw a quick response from someone who knows the line layout and data, not a distant call center.

    We’ve seen some products from trading groups or contract-fillers ship with extended lot numbers unrelated to the site where the vaccine was produced. In contrast, our numbering cycles tie straight to line logs and reviewable data sheets within our plant. Public sector inspectors and procurement officials have direct site access, given security protocols, and global pharma partners receive original C of A packages, not relabeled or generically referenced compliance forms.

    Other injectable polio vaccines often shift spec with each campaign—sometimes due to raw material shortages or contracted site issues. EUPOLIO™ Inj. stands out for stable post-fill titers, matched over years, because our line teams work through planned maintenance cycles, not crisis schedule flips or supplier-initiated downtime. This discipline also supports lower out-of-spec rejection rates and greatly reduces surprise recalls. Fewer missed shipments. Fewer surprise surcharges due to global supply chain swings.

    Building Trust Over Years, Not Transactions

    We sit with immunization managers year after year, talking through vaccine delivery plans. They don’t just want fast shipments. They want to know what’s in each product lot, how much is on the way, and that their forecasting aligns with how production and batch release really happens in the plant. With EUPOLIO™ Inj., open plant-door days for partners mean program leads walk the line, see the bottling, meet the shift leader. No third-party brokers, no confusion about where each lot originated.

    Long-term study data, submitted to regulators, gets reviewed routinely by visiting auditors. We support real-world effectiveness trials by making retained samples available for backend analysis, not just data cut-outs. Several of our largest global health partners offer feedback cycles directly to our QA and process teams. Changes to the line—automation upgrades, additional online analytics—go in with their input in mind.

    Solving Key Issues in Polio Vaccine Production

    The challenge with injectable poliovirus vaccines has always been linking large-scale, cost-managed production to robust inactivation and product safety. Live-virus facilities require the utmost care—our yearly biosecurity drills highlight containment practices not as theory, but as reflex for everyone who steps on the plant floor. Waste streams leave the facility only after chemical and thermal treatment, with ongoing monitoring for trace viral material. Our process scrubs everything, including the air in high-grade rooms, to reduce operator risk and environmental exposure beyond compliance.

    Downstream, as batches approach final bottling, every transfer hoses, clamps, or filter cartridge has a sign-off in real time, logged by badge. Data from line sensors and in-process analytics is not just stored, it is read by operators who own their shifts—seeing trends before a nonconformity hits spec. This hands-on management shrinks risks from equipment drift, raw material lot variability, or outside disruptions.

    Disruptions don’t always show up as spiked data: international transport and customs hang-ups pose a challenge to stability claims for any cold-chain product. Our global shipping office tracks all air and ground shipments, reviewing GPS and logger feedback upon receipt at centralized depots. If a thermal event or physical shock is noticed anywhere on the trip, that batch gets isolated for data review and re-testing before approval or destruction. Front-line health program managers can trace this process live through secure dashboards, seeing product movement in hours, not days.

    Product Longevity and User Confidence

    EUPOLIO™ Inj. achieves a shelf profile suitable for broad campaign and routine use in diverse climates. We work with partners from equatorial Africa to temperate Europe, adjusting packaging and secondary insulation not as an afterthought, but as a core specification managed by our line quality teams. Used with standard syringes and refrigerators, clinics can handle product disposition without complex training or new equipment. End-of-life for vials, stoppers, and packaging fits established medical waste streams with known protocols. Every label carries a serial and QR link to online certificate data, not just for procurement, but for batch-endpoint tracing years down the line.

    Batch stability and analytical retention samples live in our in-house cold rooms for several years, supporting post-market review in event of campaign anomalies. Field teams want stability data, but also visual and product recall details. We make these accessible through our secure web portals, supporting local program teams and national reporting offices directly. No one has to wait weeks or go through convoluted chains to get production records or clarification.

    Towards Future Enhancements and Industry Collaboration

    Continuous improvement defines our culture. Internal line reviews meet regularly with outside experts in virology, supply chain management, and pharmacovigilance. User feedback—whether from nurses running large campaigns or city health officials—feeds into the next run. Upgrades to inactivation steps, faster analytical assays, and new bottle capping lines follow from documented lessons in the field, not just in lab pilot runs.

    We talk directly with ministries, NGOs, and global vaccine initiatives about upcoming changes, not just marketing rollouts. Programming in-house automation and real-time sensor systems gives quicker deviation detection and lot-release decisions, reducing batch-release time for urgent campaigns. All data from these systems stays accessible to our regulatory and partner review teams—no redacted summaries, no aggregation hiding lot-level truth.

    Availability, Regulatory Oversight, and Batch Integrity

    Launch timing, batch release frequency, and tracked lot shipment remain key for keeping immunization schedules on target. EUPOLIO™ Inj. comes through direct allocation to partners and governments, without last-minute pricing or supply amendments from outside distributors. We maintain a rolling production forecast six months ahead, offering public-sector partners visibility for their annual procurement cycles.

    Regulatory data, including batch release, quality control analytics, and line records, get reviewed by both our national inspectors and international agencies as needed. Each batch’s journey, from upstream virus culture, through split and inactivation, filtration and fill, right to capping and shipment, is documented—accessible for full review by authorized parties under signed data protection.

    Our Commitment—Not Just a Product, but a Promise

    Years of direct experience making poliovirus vaccine bulk and finished products have taught us the value of accountability. EUPOLIO™ Inj. carries forward that commitment: clarity in where it comes from, how it’s built, and who stands behind it—every time. From plant floor engineer to the regulatory chemist reviewing titres, each batch reflects thousands of choices and checks, all with one aim: safety and reliability for the world’s children.

    Direct Dialogue: Input from the Field Shapes Tomorrow

    No two immunization runs look exactly alike, but every successful campaign shares something in common: partners who listen, adapt, and stay present through the unpredictable days. We don’t just accept questions after shipment; we seek them out, using field input to plan next season’s builds and to cross-check assumptions against real-world events. When a nurse in rural Kenya or the supply manager in Peru sees an issue with a batch, that report comes back to our internal audit and risk teams, fueling both immediate fixes and annual improvements.

    Most of our line operators started out handling smaller volume bioreactors or material prep stations and stayed on because ownership matters. They know the quirks of every valve or control loop. This hands-on, eyes-on mindset creates a setting where product changes from “just another batch” to a deliverable the whole team invests in. Partner surveys and feedback form part of annual training, so every pair of hands on the line works with public health impact in mind, not just a production target.

    Looking Forward: Scalability, Partnership, and Industry Learning

    EUPOLIO™ Inj. represents not just a stable, high-quality poliovirus inactivated bulk, but a flexible, open-door approach to partnership. As new guidelines or target titer ranges emerge, or as countries shift from trivalent to bivalent campaigns post-eradication, our plant adapts in collaboration with lead scientists and procurement officials. Trials for higher throughputs or rapid lot release wind down only when product consistency stays proven through both quantitative and qualitative markers.

    Auditors from both local and international agencies visit our facility each year—not just for compliance review, but to sit with line leads, trace process controls, and participate in equipment calibration or batch simulation. Collaboration grows through demonstration, not just claims. The gaps between regulatory expectation and production reality close fastest when data lives onsite and processes stay open for view, not buried in third-party ledgers.

    The Path Ahead—Reliability Built Into Every Lot

    With every batch of EUPOLIO™ Inj. shipped, our teams remember who ultimately uses the product: health workers, caregivers, and the community. Demands for reliability, security, and rapid problem-solving shape our daily work. No product can claim perfection, but ongoing vigilance, real-time feedback, and hands-on care in every process step move each run closer to that mark. EUPOLIO™ Inj. reflects collective years spent measuring, checking, and standing by what our plant delivers—not just once, but every day, year after year.